A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).

被引：5
|
作者：
Abali, Huseyin
Yalcin, Suayib
Onal, Huseyin Cem
Dane, Faysal
Oksuzoglu, Berna
Ozdemir, Nuriye
Mertsoylu, Huseyin
Artac, Mehmet
Camci, Celalettin
Karabulut, Bulent
Basal, Fatma Bugdayci
Budakoglu, Burcin
Sendur, Mehmet Ali Nahit
Goktas, Burce
Ozdener, Fatih
Calisgan, Arzu
机构：
[1] Acibadem Univ, Adana, Turkey
[2] Hacettepe Univ, Ankara, Turkey
[3] Baskent Univ, Radiat Oncol, Adana, Turkey
[4] Marmara Univ, Istanbul, Turkey
[5] Dr Abdurrahman Yurtaslan Ankara Onkol Training &, Ankara, Turkey
[6] Ankara Numune Training & Res Hosp, Ankara, Turkey
[7] Baskent Univ, Adana, Turkey
[8] Necmettin Erbakan Univ, Meram Sch Med, Konya, Turkey
[9] Gaziantep Univ, Gaziantep, Turkey
[10] Ege Univ, Izmir, Turkey
[11] Yildirim Beyazit Univ, Fac Med, Dept Med Oncol, Ankara, Turkey
[12] Roche Pharmaceut, Istanbul, Turkey
[13] Medstats Consulting, Istanbul, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps182
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS182
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A study of the combination of oxaliplatin, capecitabine, and trastuzumab and chemo-radiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastroesophageal junction cancer (TOXAG study).
    Abali, Huseyin
    Yalcin, Suayib
    Onal, Cem
    Dane, Faysal
    Oksuzoglu, Berna
    Ozdemir, Nuriye
    Mertsoylu, Huseyin
    Artac, Mehmet
    Camci, Celaletdin
    Karabulut, Bulent
    Basal, Fatma Bugdayci
    Budakoglu, Burcin
    Sendur, Mehmet Ali Nahit
    Goktas, Burce
    Ozdener, Fatih
    Baygul, Arzu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study
    Abali, Huseyin
    Yalcin, Suayib
    Onal, Huseyin C.
    Dane, Faysal
    Oksuzoglu, Berna
    Ozdemir, Nuriye
    Mertsoylu, Huseyin
    Artac, Mehmet
    Camci, Celaletdin
    Karabulut, Bulent
    Basal, Fatma B.
    Budakoglu, Burcin
    Sendur, Mehmet A. N.
    Goktas, Burce
    Ozdener, Fatih
    Baygul, Arzu
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (07): : 301 - 307
  • [3] Pembrolizumab in combination with trastuzumab for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    Shah, Shivendra
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (08): : 4647 - 4656
  • [4] Phase II study of trastuzumab in combination with capecitabine and oxaliplatin in patients with advanced gastric cancer
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Park, Young Soo
    Park, Sook Ryun
    Kim, Jong Gwang
    Han, Hye-Suk
    Chung, Ik-Joo
    Song, Eun-Kee
    Lee, Kyung Hee
    Kang, Seok Yun
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [5] Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: Results of a multicenter phase I/II study
    Stein, Alexander
    Arnold, Dirk
    Thuss-Patience, Peter C.
    Moehler, Markus
    Grothe, Wilfried
    Seufferlein, Thomas
    Reinacher-Schick, Anke
    Geissler, Michael
    Hofheinz, Ralf-Dieter
    Schmoll, Hans-Joachim
    ACTA ONCOLOGICA, 2014, 53 (03) : 392 - 398
  • [6] Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study
    Zaanan, Aziz
    Palle, Juliette
    Soularue, Emilie
    Leroy, Florence
    Louafi, Samy
    Tougeron, David
    Manfredi, Sylvain
    Artru, Pascal
    Pozet, Astrid
    Taieb, Julien
    TARGETED ONCOLOGY, 2018, 13 (01) : 107 - 112
  • [7] Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study
    Aziz Zaanan
    Juliette Palle
    Emilie Soularue
    Florence Leroy
    Samy Louafi
    David Tougeron
    Sylvain Manfredi
    Pascal Artru
    Astrid Pozet
    Julien Taieb
    Targeted Oncology, 2018, 13 : 107 - 112
  • [8] Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
    Gullo, Irene
    Grillo, Federica
    Molinaro, Luca
    Fassan, Matteo
    De Silvestri, Annalisa
    Tinelli, Carmine
    Rugge, Massimo
    Fiocca, Roberto
    Mastracci, Luca
    ENDOSCOPY INTERNATIONAL OPEN, 2015, 3 (02) : E165 - E170
  • [9] Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer
    Ryu, Min-Hee
    Yoo, Changhoon
    Kim, Jong Gwang
    Ryoo, Baek-Yeol
    Park, Young Soo
    Park, Sook Ryun
    Han, Hye-Suk
    Chung, Ik Joo
    Song, Eun-Kee
    Lee, Kyung Hee
    Kang, Seok Yun
    Kang, Yoon-Koo
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (04) : 482 - 488
  • [10] PHASE 2 STUDY OF TELATINIB IN COMBINATION WITH CAPECITABINE AND CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED CANCER OF THE STOMACH OR GASTRO-ESOPHAGEAL JUNCTION (GEJ)
    Alsina, M.
    Ajani, J. A.
    Ko, A. H.
    Garcia De Paredes, M. L.
    Rivera, F.
    Schwartzberg, L.
    Phan, A. T.
    Whiteside, M.
    Kunkel, L. A.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 229 - 229
12345